X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (167796) 167796
Newsletter (6899) 6899
Newspaper Article (3224) 3224
Magazine Article (582) 582
Book / eBook (124) 124
Transcript (78) 78
Book Chapter (69) 69
Conference Proceeding (46) 46
Dissertation (35) 35
Web Resource (27) 27
Publication (26) 26
Reference (15) 15
Streaming Video (6) 6
Report (4) 4
Journal / eJournal (3) 3
Government Document (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (144289) 144289
science & technology (124925) 124925
life sciences & biomedicine (118947) 118947
female (78925) 78925
oncology (66114) 66114
male (65947) 65947
middle aged (51708) 51708
cancer (46787) 46787
animals (45215) 45215
aged (44397) 44397
antineoplastic agents - administration & dosage (43514) 43514
adult (40539) 40539
antineoplastic agents - therapeutic use (38871) 38871
chemotherapy (33060) 33060
antineoplastic combined chemotherapy protocols - therapeutic use (32452) 32452
antineoplastic agents (31600) 31600
treatment outcome (29711) 29711
antimitotic agents (28389) 28389
care and treatment (26976) 26976
pharmacology & pharmacy (24433) 24433
mice (23986) 23986
antineoplastic agents - pharmacology (22617) 22617
antineoplastic agents - adverse effects (21406) 21406
research (19841) 19841
cell line, tumor (19754) 19754
neoplasms - drug therapy (17463) 17463
medicine & public health (15013) 15013
aged, 80 and over (14628) 14628
drug therapy (14343) 14343
health aspects (13948) 13948
analysis (13928) 13928
hematology (13517) 13517
breast neoplasms - drug therapy (13410) 13410
dose-response relationship, drug (13299) 13299
antineoplastic combined chemotherapy protocols - adverse effects (12855) 12855
drug administration schedule (12516) 12516
tumors (12372) 12372
breast cancer (11622) 11622
combined modality therapy (11472) 11472
prognosis (11216) 11216
retrospective studies (10876) 10876
apoptosis (10821) 10821
lung neoplasms - drug therapy (10511) 10511
metastasis (10400) 10400
antineoplastic combined chemotherapy protocols - administration & dosage (10333) 10333
abridged index medicus (10203) 10203
apoptosis - drug effects (10146) 10146
disease-free survival (10097) 10097
cisplatin - administration & dosage (10067) 10067
neoplasm staging (9863) 9863
time factors (9055) 9055
cancer therapies (9014) 9014
adolescent (8987) 8987
clinical trials (8853) 8853
hematology, oncology and palliative medicine (8610) 8610
survival rate (8607) 8607
doxorubicin - administration & dosage (8426) 8426
survival analysis (8268) 8268
dosage and administration (8176) 8176
cell proliferation - drug effects (8168) 8168
rats (8079) 8079
antineoplastic agents - pharmacokinetics (7941) 7941
fluorouracil - administration & dosage (7574) 7574
follow-up studies (7570) 7570
mice, nude (7510) 7510
drugs (7505) 7505
clinical trials as topic (7318) 7318
drug delivery systems (7304) 7304
surgery (7115) 7115
oncology, experimental (7113) 7113
paclitaxel - administration & dosage (7103) 7103
drug therapy, combination (7046) 7046
risk factors (6985) 6985
antineoplastic agents, phytogenic - administration & dosage (6981) 6981
xenograft model antitumor assays (6895) 6895
breast neoplasms - pathology (6803) 6803
antineoplastic agents - chemistry (6712) 6712
child (6594) 6594
cell survival - drug effects (6562) 6562
patients (6543) 6543
physical sciences (6388) 6388
chemistry (6227) 6227
neoplasm metastasis (6176) 6176
biochemistry & molecular biology (6154) 6154
deoxycytidine - analogs & derivatives (6113) 6113
medical research (6113) 6113
carcinoma, non-small-cell lung - drug therapy (6096) 6096
cyclophosphamide - administration & dosage (6075) 6075
administration, oral (6040) 6040
chemotherapy, adjuvant (5995) 5995
pharmacology/toxicology (5979) 5979
mice, inbred balb c (5902) 5902
cancer research (5861) 5861
drug resistance, neoplasm (5831) 5831
toxicity (5807) 5807
cisplatin (5655) 5655
prospective studies (5637) 5637
young adult (5509) 5509
science & technology - other topics (5362) 5362
drug synergism (5292) 5292
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (51) 51
Online Resources - Online (28) 28
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (16) 16
Collection Dvlpm't (Acquisitions) - Vendor file (8) 8
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
Credit Valley Hospital - Stacks (2) 2
Scarborough Hospital - Birchmount (2) 2
Humber River Regional Hospital - Online (1) 1
Lakeridge Health Sciences - Online (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (171002) 171002
Japanese (4582) 4582
German (1677) 1677
French (1551) 1551
Chinese (1076) 1076
Russian (968) 968
Italian (502) 502
Spanish (458) 458
Polish (288) 288
Portuguese (189) 189
Hungarian (184) 184
Dutch (128) 128
Czech (111) 111
Danish (91) 91
Norwegian (72) 72
Swedish (69) 69
Ukrainian (38) 38
Hebrew (36) 36
Romanian (24) 24
Serbian (23) 23
Croatian (21) 21
Bulgarian (17) 17
Finnish (17) 17
Korean (16) 16
Lithuanian (14) 14
Turkish (14) 14
Slovak (10) 10
Arabic (2) 2
Amharic (1) 1
Bosnian (1) 1
Greek (1) 1
Kurdish (1) 1
Persian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer chemotherapy and pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
ACS nano, ISSN 1936-0851, 02/2017, Volume 11, Issue 2, pp. 2227 - 2238
Poor tumor penetration is a major challenge for the use of nanoparticles in anticancer therapy. Moreover, the inability to reach hypoxic tumor cells that are... 
hypoxia | cancer | nanoparticles | tumor penetration | iRGD | photodynamic therapy | Physical Sciences | Chemistry | Materials Science | Nanoscience & Nanotechnology | Technology | Materials Science, Multidisciplinary | Science & Technology - Other Topics | Chemistry, Multidisciplinary | Chemistry, Physical | Science & Technology | Prodrugs - administration & dosage | Hypoxia - drug therapy | Injections, Intravenous | Photosensitizing Agents - chemistry | Reactive Oxygen Species - metabolism | Nanoparticles - chemistry | Apoptosis - drug effects | Prodrugs - chemistry | Antineoplastic Agents - administration & dosage | Indocyanine Green - pharmacology | Photochemotherapy | Drug Delivery Systems | Tirapazamine - chemistry | Photosensitizing Agents - administration & dosage | Tissue Distribution | Indocyanine Green - chemistry | Photosensitizing Agents - pharmacology | Antineoplastic Agents - pharmacology | Molecular Structure | Tumor Cells, Cultured | Indocyanine Green - administration & dosage | Tirapazamine - administration & dosage | Tirapazamine - pharmacology | Antineoplastic Agents - chemistry | Reactive Oxygen Species - analysis | Animals | Cell Proliferation - drug effects | Mice | Nanoparticles - administration & dosage | Prodrugs - pharmacology | Drug Screening Assays, Antitumor | Index Medicus | Nanoparticles | Drugs | Therapy | Drug delivery systems | Photodynamic therapy | Penetration | Tumors | Anticancer properties | Hypoxia | Tumor Penetration | Photodynamic Therapy | Cancer
Journal Article
The oncologist (Dayton, Ohio), ISSN 1549-490X, 05/2017, Volume 22, Issue 7, pp. 823 - 833
...) has become standard of care. These agents are administered until disease progression or unacceptable toxicity occurs... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma |